Bavarian Nordic
200.1
DKK
-2.53 %
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
48 following
www.bavarian-nordic.com/investor.aspx
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Revenue
7.06B
EBIT %
21.28 %
P/E
10.42
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
BAVA
Daily low / high price
198.85 / 203.6
DKK
Market cap
15.77B DKK
Turnover
16.95M DKK
Volume
84K
Latest videos
Financial calendar
Interim report
15.11.2024
Annual report
05.03.2025
General meeting
09.04.2025
Interim report
09.05.2025
Interim report
22.08.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
ATP Group | 10.1 % | 10.1 % |
Invesco | 5.0 % | 5.0 % |
ShowingAll content types
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine
Bavarian Nordic opjusterer sine økonomiske forventninger til 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools